Drugs / SIBP-02
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT04361279 | Jul 2019 → May 2022 | diffuse large B-cell lymphoma | Shanghai Institute Of Biological Products | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SIBP-02 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04361279 ↗ |
| Route | Intravenous | “Biological: SIBP-02, 375 mg/m2, intravenous infusion, administered on day1.” NCT04361279 ↗ |